Philip W. Iversen

6.2k total citations · 1 hit paper
59 papers, 3.4k citations indexed

About

Philip W. Iversen is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philip W. Iversen has authored 59 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 22 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philip W. Iversen's work include DNA Repair Mechanisms (7 papers), Cancer-related Molecular Pathways (7 papers) and Computational Drug Discovery Methods (7 papers). Philip W. Iversen is often cited by papers focused on DNA Repair Mechanisms (7 papers), Cancer-related Molecular Pathways (7 papers) and Computational Drug Discovery Methods (7 papers). Philip W. Iversen collaborates with scholars based in United States, Spain and United Kingdom. Philip W. Iversen's co-authors include Jeremy R. Graff, Brian J. Eastwood, G. Sitta Sittampalam, Blake Lee Neubauer, Karen L. Cox, Bruce W. Konicek, Marı́a José Lallena, Fritz F. Parl, James G. Herman and Edward Gabrielson and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Philip W. Iversen

59 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

2014 446 citations Lawrence M. Gelbert, Shufen Cai et al. Investigational New Drugs profile →

Peers

Countries citing papers authored by Philip W. Iversen

Since Specialization

Citations

This map shows the geographic impact of Philip W. Iversen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip W. Iversen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip W. Iversen more than expected).

Fields of papers citing papers by Philip W. Iversen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip W. Iversen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip W. Iversen. The network helps show where Philip W. Iversen may publish in the future.

Co-authorship network of co-authors of Philip W. Iversen

This figure shows the co-authorship network connecting the top 25 collaborators of Philip W. Iversen. A scholar is included among the top collaborators of Philip W. Iversen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip W. Iversen. Philip W. Iversen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Persistence and gazing at humans during an unsolvable task in dogs: The influence of ownership duration, living situation, and prior experience with humans 2022 ·Behavioural Processes ·(unknown), Philip W. Iversen, (unknown), (unknown), Jennifer J. Templeton	3
2	Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies 2019 ·The AAPS Journal ·Maria Garcia‐Cremades, Celine Pitou, Philip W. Iversen, Iñaki F. Trocóniz	8
3	Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling 2018 ·Clinical Cancer Research ·Michele Dowless, Caitlin D. Lowery, Terry J. Shackleford, (unknown), Jennifer Stephens, (unknown), Wayne Blosser, Simone Gupta, Julie Stewart, Yue Webster, Jack Dempsey, (unknown), Philip J. Ebert, Philip W. Iversen, Jonathan B. Olsen, Xueqian Gong, Sean G. Buchanan, Peter J. Houghton, Louis F. Stancato	47
4	Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade 2018 ·Journal for ImmunoTherapy of Cancer ·Rikke Holmgaard, David Schaer, Yanxia Li, Stephen Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, (unknown), Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos, Kyla Driscoll	267
5	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts 2018 ·Journal of Pharmacology and Experimental Therapeutics ·Zinnia P. Parra‐Guillén, Víctor Mangas‐Sanjuán, Maria Garcia‐Cremades, Iñaki F. Trocóniz, Gary Mo, Celine Pitou, Philip W. Iversen, Johan Wallin	8
6	Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer 2018 ·European Journal of Pharmaceutical Sciences ·Maria Garcia‐Cremades, Celine Pitou, Philip W. Iversen, Iñaki F. Trocóniz	16
7	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations 2017 ·Clinical Cancer Research ·(unknown), Gregory P. Donoho, Philip W. Iversen, Youyan Zhang, Robert D. Van Horn, Amélie Forest, Ruslan D. Novosiadly, Yue Webster, Philip J. Ebert, Steven M. Bray, Jason C. Ting, Amit Aggarwal, James R. Henry, Ramón V. Tiu, Gregory D. Plowman, Sheng‐Bin Peng	39
8	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1 2017 ·Oncogene ·S-H Chen, (unknown), (unknown), Robert D. Van Horn, Taiqi Yin, L. Julie Huber, T. Burke, Jason R. Manro, Philip W. Iversen, Wenjuan Wu, Shripad V. Bhagwat, Richard P. Beckmann, Ramón V. Tiu, Sean G. Buchanan, (unknown)	58
9	Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth 2016 ·Molecular Cancer Therapeutics ·Michèle C. Smith, Mary M. Mader, James A. Cook, Philip W. Iversen, Rose T. Ajamie, E.J. Perkins, Laura J. Bloem, (unknown), David A. Barda, (unknown), Douglas J. Zeckner, Debra A. Young, Manuel Sánchez-Félix, Gregory P. Donoho, Volker Wacheck	62
10	Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model 2016 ·Journal of Pharmacology and Experimental Therapeutics ·Maria Garcia‐Cremades, Celine Pitou, Philip W. Iversen, Iñaki F. Trocóniz	9
11	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine breakdown → 2014 ·Investigational New Drugs ·Lawrence M. Gelbert, Shufen Cai, Xi Lin, Concepción Sánchez‐Martínez, Miriam Del Prado, Marı́a José Lallena, Raquel Torres, Rose T. Ajamie, Graham N. Wishart, (unknown), Blake Lee Neubauer, Jamie Young, Edward M. Chan, Philip W. Iversen, Damien M. Cronier, Emiko L. Kreklau, Alfonso de Dios	446
12	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer 2014 ·Investigational New Drugs ·Emiliano Calvo, Victor J. Chen, Mark S. Marshall, U. Ohnmacht, Scott M. Hynes, (unknown), (unknown), Darlene Barnard, Farhana F. Merzoug, Lysiane Huber, Lisa Kays, Philip W. Iversen, Antonio Calles, (unknown), Aimee Bence Lin, Nicolas Dickgreber, Thomas Wehler, Martin Sebastian	47
13	Antisense Inhibition of Survivin Expression as a Cancer Therapeutic 2011 ·Molecular Cancer Therapeutics ·Rosa A. Carrasco, Nancy B. Stamm, Eric G. Marcusson, George Sandusky, Philip W. Iversen, Bharvin K.R. Patel	102
14	The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies 2006 ·SLAS DISCOVERY ·Brian J. Eastwood, Mark W. Farmen, Philip W. Iversen, Trelia J. Craft, Jeffrey K. Smallwood, (unknown), Neil W. DeLapp, Gerald F. Smith	100
15	Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic β-adrenergic stimulation 2004 ·Journal of Molecular and Cellular Cardiology ·Michael E. Christe, Najia Jin, Xushan Wang, Kenneth E. Gould, Philip W. Iversen, (unknown), John N. Lorenz, Vivek J. Kadambi, (unknown), Laura J. Bloem	11
16	LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice 2004 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Michael Y. Sherman, Elizabeth J. Galbreath, (unknown), Darryl Ballard, Yunfei Chen, Philip W. Iversen, Beverly A. Teicher	97
17	Castration triggers growth of previously static androgen‐independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model 2004 ·The Prostate ·Mac Johnson, Philip W. Iversen, (unknown), (unknown), George E. Sandusky, Jeremy R. Graff, Blake Lee Neubauer	17
18	An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells 2000 ·Advances in Enzyme Regulation ·(unknown), Jesse R. Bewley, (unknown), Sherri L. Andis, Richard M. Schultz, Philip W. Iversen, John L. Tonkinson, C Shih	5
19	Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non—insulin-dependent diabetes mellitus 1997 ·Clinical Therapeutics ·Louis Vignati, James H. Anderson, Philip W. Iversen	43
20	Application of automatic image segmentation to tibiae and vertebrae from ovariectomized rats 1997 ·Bone ·Jeffrey D. Helterbrand, Richard E. Higgs, Philip W. Iversen, G. Tysarczyk-Niemeyer, Masahiko Sato	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact